ClinicalTrials.gg
RecruitingNCT07203742Updated Feb 17, 2026

The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Treatment

An interventional study of mandala painting in Acute Lymphoblastic Leukemia, Childhood Acute Leukemia and Acute Myeloblastic Leukaemia, sponsored by Ege University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Ege University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
4 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey — 6 open to participants now, 11 under way, 5 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Turkey.

Planned enrollment
23rd of 31
60 · median 102
Started
2025
with 2 others
No phase
15 of 38
3 open now
Primary completion
2026-08
later than 4 of 10 live
Registered
37th of 38
by date
Lead sponsor
3 of 38
Ege University

Among the 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey, this one is the 23rd largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2025, is one of 15 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 37th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

6 of the 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 4 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to examine the effect of mandala coloring activity, administered before intrathecal chemotherapy treatment in children with leukemia, on pre-procedure anxiety and fear in children. The main question this study aims to answer is:

Does mandala coloring administered before intrathecal chemotherapy treatment reduce pre-procedure anxiety and fear in children with leukemia?

Descriptive demographic data will be collected from the children who will be given mandalas. Data will be collected using an Anxiety Scale and a Fear Scale.

Read the detailed description

Acute leukemia, the most common cancer in childhood (32% in girls and boys aged 0-14), is characterized by the uncontrolled and abnormal proliferation of leukocytes in the bone marrow, where blood cells are produced. Chemotherapy agents are used in its treatment. Subsequently, intrathecal chemotherapy is administered according to the child's risk group and protocol. Intrathecal chemotherapy options include intrathecal methotrexate or a combination of intrathecal methotrexate with cytarabine and hydrocortisone. Numerous complications associated with chemotherapy may occur. These complications include fatigue, nausea and vomiting, hair loss, pancytopenia, mucositis, diarrhea, and constipation. In addition, psychological side effects such as depression, anxiety, fear, and insomnia are also frequently seen in children. Non-pharmacological methods are available for managing psychological side effects in individuals diagnosed with leukemia. These methods include psychoeducation, cognitive-behavioral therapy, art therapy, supportive psychotherapy, relaxation, and distraction techniques. In addition to these methods, mandala coloring, which can be used in many different situations, is also available. This study aims to investigate the effect of mandala coloring activity on anxiety and fear levels in children with leukemia before intrathecal treatment. The study will be conducted at the Pediatric Hematology Clinic of Ege University Faculty of Medicine Children's Hospital with a total of 60 children aged 4-12 years who are scheduled for intrathecal treatment. Children aged 4-12 years who meet the inclusion criteria and who will receive intrathecal chemotherapy due to leukemia treatment will be included in the study. The "Unmatched Control Group Model" will be used in the study, and randomization will not be performed. In this design, the intervention and control groups are planned to consist of participants with similar characteristics. To prevent/minimize interaction between groups, the control group data will be collected first. After the control group data is collected, the intervention group data will be collected. Data collection and the intervention will be carried out after the children are assigned to their groups. The SPSS 26.0 software package will be used to analyze the data obtained after the study. Frequency and percentage distributions will be used to check the distribution of participants' demographic characteristics and the normality of the data. Advanced analyses will then be performed.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Childhood Acute Leukemia
  • Acute Myeloblastic Leukaemia

Keywords

  • intrathechal chemotherapy treatment
  • anxiety
  • fear
  • mandala
  • nursing
04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient must be between 4 and 12 years of age.
  • The patient must be hospitalized and followed up at the Pediatric Hematology Clinic.
  • The patient must only be receiving leukemia treatment.
  • The patient must not have any other chronic diseases.
  • The patient must not have any systemic infections.
  • The patient has received at least two courses of intrathecal chemotherapy treatment
  • The patient does not have a diagnosis of psychological/mental symptoms as a side effect of chemotherapy treatment
  • Intrathecal treatment will be administered to the patient in accordance with the chemotherapy protocol
  • The patient and the caregiver parent are volunteers
  • The caregiver parent speaks Turkish and is open to communication.

Exclusion criteria

Exclusion Criteria:

  • Cases that do not meet the inclusion criteria will be excluded from the study.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    mandala painting

    Other: mandala painting

  • No intervention
    control

Interventions

  • Othermandala painting

    After the child and parent agree to participate in the study and the child indicates that they wish to do the mandala exercise, the child will be seated in a comfortable position to paint. Thirty minutes before the start of the intrathecal chemotherapy procedure (children who will receive intrathecal chemotherapy at the clinic are identified and scheduled the day before), the child, their parent, and a nurse independent of the study will be assessed using the "Child Anxiety Scale-State (ÇAS-D)" and the "Child Fear Scale." The mandala coloring activity will then continue until the child wishes to stop (the activity will be ensured to last at least 30 minutes). When the child is called to the procedure room for intrathecal chemotherapy, the scale assessments will be repeated. Thirty minutes after the intrathecal chemotherapy procedure is completed and the child has emerged from the effects of general anesthesia, the scales will be reassessed and recorded by the same i

06

What researchers measure

Primary outcomes

  1. Fear of intrathecal chemotherapy

    The fear that children will experience due to intrathecal chemotherapy will be collected using the "Children's Fear Scale".

    Time frame: From enrollment to 30 minutes after intrathecal chemotherapy

  2. Anxiety of intrathecal chemotherapy

    The fear that children will experience due to intrathecal chemotherapy will be collected using the "Children's Anxiety Scale".

    Time frame: From enrollment to 30 minutes after intrathecal chemotherapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Aug 2026, 11 months after the start.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 11 months is below that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Oct 2, 2025
StartActual
Sep 29, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Sep 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07203742
Lead sponsor
Ege University
Responsible party
SEDA ARDAHAN SEVGİLİ (Asst. Professor, Ege University) — Principal investigator
First posted
Oct 2, 2025
Start date
Sep 29, 2025
Primary completion
Aug 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Seda ARDAHAN SEVGİLİ, Ph.D
Contact
sedardahan@gmail.com
00902323115572 ext. 5572
Seda Ardahan Sevgili, Ph.D.
principal investigator · Ege University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion